WINNERS ANNOUNCED!
Global Generics & Biosimilars Awards 2023
25 Oct 2023 - 18:00 - 23:30
Global Generics and Biosimilars Awards 2023 poster image.

THE WINNERS HAVE BEEN ANNOUNCED!

 

Join us for the 10th anniversary of the Global Generics and Biosimilars Awards celebrating the greatest achievements and innovations across the development, authorization, marketing and distribution of global off-patent pharmaceuticals.

Co-locating with CPhI Worldwide in Barcelona, these illustrious awards provide a unique opportunity for the industry to come together to discuss future opportunities and challenges and shine a light on the companies and individuals driving positive change. Winners will be recognized across 14 categories, including Biosimilar Initiative of the Year, Leader of the Year, API Supplier of the Year and new for 2023, Campaign of the Year.

The Global Generics and Biosimilars Awards are free to enter. The judging process will take place over the summer. The finalists will be announced in September and the winners revealed at the Awards on 25 October 2023.

Key details

    Ceremony: Wednesday, 25 October, 2023

    Hotel Porta Fira, Barcelona

THE GLOBAL GENERICS & BIOSIMILARS AWARDS CATEGORIES 2023
WHO COULD ENTER

Open to any company which has acquired another company that is active in generics and/or biosimilars, or has acquired a portfolio of generic and/or biosimilar products.


WINNER
  • Biocon Biologics - acquisition of Viatris biosimilars business

FINALISTS
  • Adalvo - acquisition of Onsolis
  • Biocon Biologics - acquisition of Viatris biosimilars business
  • Rising Pharmaceuticals - acquisition of Akorn assets
  • Sandoz - acquisition of Mycamine from Astellas
  • Zentiva - acquisition of Sanofi Consumer Health brands
WHO COULD ENTER

Entries may relate to any biosimilar currently marketed, approved or in clinical development, sales and marketing initiatives, distribution agreements or other initiatives aimed at increasing biosimilar usage.


WINNER
  • Polpharma Biologics

FINALISTS
  • Accord Healthcare
  • Celltrion Healthcare
  • Lambda Therapeutic Research
  • Polpharma Biologics
  • Samsung Bioepis
  • Sandoz
  • Similis Bio
WHO COULD ENTER

Open to any generics and/or biosimilars alliance, joint venture, distribution agreement, licensing deal or similar that does not involve the acquisition of another company or a portfolio of products.


WINNER
  • Sandoz

FINALISTS
  • Accord Healthcare
  • Adalvo
  • Aurobindo Pharma
  • Biocon
  • Sandoz
  • Similis Bio
  • Zentiva
WHO COULD ENTER

This category allows industry firms and organizations to highlight outstanding campaigns used to successfully promote and highlight generics, biosimilars and value-added medicines across the world. This could include awareness campaigns, efforts to highlight key industry contributions to a wider audience, or initiatives that raise the profile of off-patent medicines for healthcare industry stakeholders.


WINNER
  • Biosimilars Canada - #MakeTheSwitch

FINALISTS
  • Association for Accessible Medicines - #4GRxANTED
  • Biosimilars Canada - #MakeTheSwitch
  • Canadian Generic Pharmaceutical Association - #PrescriptionForCanada
  • Celltrion Healthcare - the "Where’s CC (Crohn’s & Colitis)?" Campaign
  • International Generic and Biosimilar Medicines Association - Global Biosimilars Week Campaign
  • Samsung Bioepis - “Why Biosimilars” Campaign
  • Sandoz - Act4Biosimilars Action Plan
WHO COULD ENTER

Open to any company that generates at least a third, or at least US $250 million, of its annual sales from generics or biosimilars.


WINNER
  • Sandoz

FINALISTS
  • Accord Healthcare
  • Biocon Biologics
  • Celltrion Healthcare
  • Samsung Bioepis
  • Sandoz
  • STADA
WHO COULD ENTER

Open to any company that generates at least a third, or at least US$250 million, of its annual sales from generics and biosimilars. Qualification for a region is dependent on the headquarters (not tax domicile) of a company’s generics and/or biosimilars business.


WINNER: Company of the Year – Americas
  • Dr.Reddy's Americas
FINALISTS: Company of the Year – Americas
  • Amneal Pharmaceuticals
  • Coherus BioSciences
  • Dr.Reddy's Americas


WINNER: Company of the Year – Asia-Pacific
  • Samsung Bioepis
FINALISTS: Company of the Year – Asia-Pacific
  • Aurobindo Pharma
  • Beximco Pharma
  • Biocon Biologics
  • Samsung Bioepis
  • Shanghai Henlius Biotech
  • Surge Laboratories


WINNER: Company of the Year – EMEA
  • Accord Healthcare
FINALISTS: Company of the Year – EMEA
  • Accord Healthcare
  • Sandoz
  • STADA
WHO COULD ENTER

Humanitarian charity International Health Partners (IHP) has partnered with Generics Bulletin to create this Award. Entries could include: company approach to CSR, implementation, engagement plans, raining & education programmes, compulsory licensing and humanitarian aid donations.


WINNER
  • Teva Pharmaceuticals

FINALISTS
  • Accord Healthcare
  • Centrient Pharmaceuticals
  • Dr. Reddy's Laboratories
  • Eurofarma Laboratórios
  • Shanghai Henlius Biotech
  • Teva Pharmaceuticals
WHO COULD ENTER

Awarded to recognize outstanding achievements by firms or individuals that work alongside generics and biosimilars manufacturers and suppliers. These could include logistics providers, contract-research organisations, contract-manufacturers, law firms and consultants.


WINNER
  • Lambda Therapeutic Research

FINALISTS
  • Adalvo
  • Affygility Solutions
  • Biocon
  • Centrient Pharmaceuticals and Ginkgo Bioworks
  • Inoviem Scientific
  • Lambda Therapeutic Research
  • Surge Laboratories
WHO COULD ENTER

Open to any member of the senior management team of a firm within the generics or biosimilars industries. Judges will want to see how the entered leaders have best applied company values within the business environment – achieving measured and sustainable growth, driving improved performance, delivering shareholder value, implementing robust strategies, engaging staff, demonstrating market knowledge and true customer insight.


WINNER
  • Richard Saynor, Sandoz

FINALISTS
  • Anil Okay, Adalvo
  • Apurva Saraf, Cosette Pharmaceuticals
  • Paul Tredwell,Accord Healthcare EMENA
  • Peter Goldschmidt, STADA
  • Rachel Goode, Fresenius Kabi
  • Richard Saynor, Sandoz
WHO COULD ENTER

Awarded to identify excellence in the regulatory sphere. This could include innovative approaches to obtaining marketing authorisations, regulatory milestones for individual companies, or developments that represent a wider breakthrough for the global generics and/or biosimilars industries.


WINNER
  • Samsung Bioepis

FINALISTS
  • Adalvo
  • Ami Lifesciences
  • Aurobindo Pharma
  • Dr. Reddy's Laboratories
  • Samsung Bioepis
  • Zentiva
Book your place to the Awards today!
HEADLINE SPONSOR

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry. IQVIA creates intelligent connections to deliver powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 86,000 employees, IQVIA conducts operations in more than 100 countries. Learn more at www.iqvia.com.

Want to sponsor an award

PREVIOUS GLOBAL GENERICS & BIOSIMILARS AWARD CEREMONIES

Want to view previous Global Generics & Biosimilars Awards? Take a look back at our previous Awards and winners.
Abstract blue and green spiral.
Clinical

Global Generics and Biosimilars Awards 2022

The Global Generics and Biosimilars Awards honor the remarkable accomplishments in the development, authorization, and distribution of global off-patent pharmaceuticals.

 

Headline sponsor

Company logo of IQVIA